Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | FAAH | O00519 | 3/20 | 0.46 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 1/20 | 0.41 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | GMNN | O75496 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | CETP | P11597 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15318852 | 1.00 | MEN1 (0.46) | MEN1KMT2AFAAHSOAT1TP53 | |
| SCHEMBL28588566 | 0.82 | F7 (0.47) | MEN1KMT2AFAAHSOAT1TP53 | |
| SCHEMBL3270488 | 0.82 | F7 (0.47) | MEN1KMT2AFAAHSOAT1TP53 | |
| SCHEMBL23829594 | 0.82 | CYP3A4 (0.43) | MEN1KMT2AFAAHTP53CYP1A2 | |
| SCHEMBL1771481 | 0.82 | F7 (0.47) | MEN1KMT2AFAAHSOAT1TP53 | |
| SCHEMBL23829593 | 0.82 | CYP3A4 (0.43) | MEN1KMT2AFAAHTP53CYP1A2 | |
| SCHEMBL28718806 | 0.81 | CYP1A2 (0.43) | MEN1KMT2AFAAHSOAT1TP53 | |
| SCHEMBL29050792 | 0.80 | F7 (0.46) | MEN1KMT2AFAAHSOAT1TP53 | |
| SCHEMBL28714907 | 0.79 | CA1 (0.44) | MEN1KMT2AFAAHSOAT1TP53 | |
| SCHEMBL10584843 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023206580-A1 | DURLOBACTAM CRYSTALLINE FORMS | ENTASIS THERAPEUTICS LIMITED (GB) | 2023-11-02 | — | — | WO | disclosed |
| EP-3512851-B1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LTD (GB) | 2022-07-06 | — | — | EP | disclosed |
| CN-114591223-A | Beta-lactamase inhibitor compounds | 恩塔西斯治疗有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-109715630-B | Beta-lactamase inhibitor compounds | 恩塔西斯治疗有限公司 | 2022-02-22 | — | — | CN | disclosed |
| EP-3512851-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | Entasis Therapeutics Limited (GB) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018053215-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LIMITED (GB) | 2018-03-22 | — | — | WO | disclosed |
| EP-2834239-A1 | HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS | Astrazeneca AB (SE) | 2015-02-11 | — | — | EP | disclosed |
| WO-2013150296-A1 | HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS | ASTRAZENECA AB (SE) | 2013-10-10 | — | — | WO | disclosed |